Fludarabine
Recurrent Adult Diffuse Large Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, ChinaSmall moleculePhase 4 / ApprovedActive
BBB
76/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 68/ 100
- Competitive Position
- 89/ 100
Competitive context
14 Active assets in the Recurrent Adult Diffuse Large Cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FILGRASTIM Ruijin Hospital | Phase 3 | BBB |
CYCLOSPORIN A Fred Hutchinson Cancer Center | Phase 3 | BBB |
Busulphan Washington University School of Medicine | Phase 3 | BBB |
Cediranib National Cancer Institute (NCI) | Phase 2 | BB |
Bendamustine St. Petersburg State Pavlov Medical University | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →